Program
Leuprolide
Also written as “Leuprorelin”, “Leuprolide acetate” and “Leuprolide Acetate”.
Its studies are mostly in Prostatic Neoplasms · Puberty, Precocious · Alzheimer Disease · Endometriosis · Breast Neoplasms, led by 18 companies.
Drug pageLeuprolide: every studyMany companies study it; this page follows only the 38 they lead. All 153 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 60 open or running | phase 4since Apr 23, 2015 | Oct 16, 2008 | none ahead |
| Abbottits history only | 50 open or running | phase 3since Feb 20, 2008 | Mar 20, 2003 | none ahead |
| AbbVieits history only | 30 open or running | phase 4since Jul 9, 2010 | Apr 24, 2008 | none ahead |
| Daewoong Pharmaceuticalits history only | 31 open or running | phase 4since Jul 3, 2012 | Jul 3, 2012 | none ahead |
| GP-Pharmits history only | 30 open or running | phase 3since Aug 8, 2005 | Aug 8, 2005 | none ahead |
| Astellas Pharmaits history only | 20 open or running | phase 4since Jan 25, 2017 | Sep 19, 2006 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 20 open or running | phase 1since May 23, 2016 | May 23, 2016 | none ahead |
| Johnson & Johnsonits history only | 20 open or running | phase 2since Jun 17, 2009 | Jun 17, 2009 | none ahead |
| Oakwood Laboratoriesits history only | 20 open or running | phase 3since Jan 26, 2004 | Jan 26, 2004 | none ahead |
| Voyager Pharmaceuticalits history only | 20 open or running | phase 2since Jun 25, 2003 | Jun 25, 2003 | none ahead |
| Bharat Serums and Vaccinesits history only | 10 open or running | phase 3since May 31, 2021 | May 31, 2021 | none ahead |
| Dongkook Pharmaceuticalits history only | 10 open or running | phase 3since Jun 13, 2024 | Jun 13, 2024 | none ahead |
| Enteris BioPharmaits history only | 10 open or running | phase 2since Oct 15, 2021 | Oct 15, 2021 | none ahead |
| Lee's Pharmaceuticalits history only | 10 open or running | no phasesince Aug 30, 2018 | Aug 30, 2018 | none ahead |
| LG Chem | 11 open or running | phase 4since Jul 6, 2026 | Jul 6, 2026 | Aug 30, 2029phase 4 · NCT07710430 |
| Peptronits history only | 10 open or running | phase 1since Mar 2, 2021 | Mar 2, 2021 | none ahead |
| Tolmarits history only | 10 open or running | phase 3since May 5, 2015 | May 5, 2015 | none ahead |
| Zodiac Produtos Farmaceuticosits history only | 10 open or running | phase 4since Mar 11, 2022 | Mar 11, 2022 | none ahead |
Also a collaborator on its studies: Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of LG Chem only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 6, 2026First study: phase 4 study in Puberty, PrecociousFirst studyNCT07710430 · 43 planned · South Korea
Ahead
- Aug 30, 2029Primary completion: phase 4 study in Puberty, PrecociousNCT07710430
TargetBeta
“Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Other programs on GNRHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| triptorelinrule | Ipsen | phase 4 | 21 |
| Goserelinrule | AstraZeneca | phase 4 | 14 |
| linzagolixrule | Kissei Pharmaceutical | phase 3 | 14 |
| GnRH Antagonist SHR7280 | Jiangsu HengRui Medicine | phase 3 | 10 |
| Gonadotropin-Releasing Hormonerule | Ferring Pharmaceuticals | phase 3 | 5 |
| leuprolide mesylaterule | foresee-pharmaceuticals-co-ltd | phase 3 | 3 |
Studies
The one study LG Chem leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07710430Puberty, Precocious · South Korea | 4 | Recruiting | Aug 30, 2029 | 43 |
How it is read
Names in the registry
- “Leuprorelin”, 4 entries
- “Leuprolide acetate”, 4 entries
- “Leuprolide”, 2 entries
- “Leuprolide Acetate”, 2 entries
- “TAP-144-SR(6M)”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 21 studies
- Puberty, Precocious, 10 studies
- Alzheimer Disease, 2 studies
- Endometriosis, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.